Leukemia can be misdiagnosed, and it happens more often than most people assume. A retrospective study of over 400 adult leukemia cases at a single center found that roughly 45 percent experienced a delayed diagnosis, with the time from first symptoms to confirmation stretching anywhere from a month to over nine months. The reasons range from symptoms that look identical to common infections, to lab findings that mimic a simple vitamin deficiency, to cognitive shortcuts that lead doctors away from considering cancer at all. Understanding where and why the diagnostic process breaks down matters for patients and families navigating unexplained blood abnormalities.
How Long Delays Typically Last
Quantifying diagnostic delay is tricky because studies measure it differently. Some rely on patient recall, others pull from medical records, and still others combine both. A rapid review of studies on blood cancer diagnosis found reported delays ranging from 30 days to seven months, depending on the method and the population studied.1PubMed Central. What causes delays in diagnosing blood cancers? A rapid review of the evidence A study focusing specifically on childhood acute lymphoblastic leukemia in a tertiary hospital found a median total diagnostic delay of 60 days.2Journal of Pharmacology Pharmaceutics & Pharmacovigilance. Physician Delay for Delayed Diagnosis of Acute Lymphoblastic Leukemia among Children in a Tertiary Care Hospital Among adults in Qatar, the median time from symptom onset to leukemia diagnosis was 28 days across all cases, but for those specifically flagged as delayed, the median climbed to 44 days, and some individuals waited nearly 280 days.3PubMed Central. Diagnosis Challenges in Adult Leukemia: Insights From a Single-Center Retrospective Study in Qatar (2016-2021)
These numbers capture the time between a patient first noticing something wrong and a confirmed diagnosis landing in a chart. They do not account for a separate category of misdiagnosis: cases where leukemia is initially suspected but turns out to be something benign, or cases where a benign condition is mistaken for leukemia and unnecessary treatment is started. Both directions of error happen, and they have different causes.
When Infections Look Like Leukemia, and Vice Versa
Epstein-Barr virus, the pathogen behind infectious mononucleosis, is one of the most common sources of diagnostic confusion. EBV targets the same types of cells that go haywire in leukemia, and it can flood the bloodstream with abnormal-looking white cells that, under a microscope, resemble leukemic blasts. Two documented adult cases involved patients initially diagnosed with acute leukemia based on atypical cells in the blood. One turned out to be classic mono; the other had an EBV-triggered inflammatory syndrome called hemophagocytic lymphohistiocytosis.4PubMed Central. Epstein-barr virus infection masquerading as acute leukemia: a report of two cases and review of literature
The confusion also runs in the opposite direction. A five-year-old girl presented with fever, swollen lymph nodes, an enlarged liver and spleen, and a positive Monospot test, which is a quick screening test for mono. Everything pointed to EBV infection. But her blood counts kept worsening instead of improving, and tumor-related markers shot up. Further testing revealed that the Monospot had been a false positive. She actually had precursor B-cell acute lymphoblastic leukemia.5PubMed Central. A positive Monospot test misleads: Acute lymphoblastic leukemia presenting as infectious mononucleosis in a 5-year-old The Monospot test is convenient but not perfectly specific, and a positive result in the setting of an abnormal blood count can steer the clinical team away from more aggressive investigation.
Vitamin B12 Deficiency and the Leukemia Lookalike
One of the more surprising mimics of leukemia is a simple nutritional deficiency. Severe vitamin B12 deficiency can cause the bone marrow to produce bizarre-looking cells with features that, to a hematologist examining a bone marrow biopsy, look disturbingly close to the immature “blast” cells seen in acute myeloid leukemia. Low counts across all blood cell lines, oversized red cells, and oddly segmented white cells round out a picture that can fool even experienced pathologists.
In one published case, a patient was referred to a major medical center with a suspected diagnosis of acute myeloid leukemia based on peripheral blood smear and bone marrow biopsy findings. The treating team was considering starting chemotherapy. It turned out the patient was profoundly B12-deficient, and vitamin supplementation alone normalized the bone marrow.6PubMed Central. Vitamin B12 deficiency mimicking acute leukemia A separate report described two patients in identical scenarios: bone marrow smears suspicious enough that induction chemotherapy was discussed, with both ultimately found to have pernicious anemia and no cancer whatsoever.7PubMed. Pernicious anemia: presentations mimicking acute leukemia Checking a B12 level is cheap and fast, but in the urgency of a suspected leukemia workup, it can get overlooked.
The Pediatric Trap of Bone Pain and Swollen Joints
Children with leukemia do not always present the way parents or doctors expect. While easy bruising and persistent fevers get the most attention in public awareness campaigns, bone and joint pain is a leading early symptom in kids, and it frequently leads clinicians down the wrong path. In a study of 296 children with ALL, about 18 percent had prominent bone pain that overshadowed every other sign of the disease. Those children tended to have blood counts close to normal, which made the diagnosis even harder to suspect. On average, they experienced symptoms more than two weeks longer before being diagnosed compared to children whose blood counts were obviously abnormal.8PubMed. Bone pain as an initial symptom of childhood acute lymphoblastic leukemia: association with nearly normal hematologic indexes
When joint swelling accompanies the pain, the risk of misdiagnosis jumps further. A study of 286 children with ALL found that about 18.5 percent presented with localized joint pain, and half of those had visible signs of arthritis. The suspected diagnoses before leukemia was identified included reactive arthritis, bone infection, and juvenile idiopathic arthritis.9PubMed. Arthritis as presenting manifestation of acute lymphoblastic leukaemia in children At least one documented case describes a child initially diagnosed with juvenile idiopathic arthritis whose leukemia diagnosis was delayed because the joint symptoms dominated the clinical picture and blood work appeared unremarkable.10PubMed Central. A case of acute lymphoblastic leukemia mimicking juvenile idiopathic arthritis For families dealing with unexplained bone or joint pain in a child, a normal blood count does not rule out leukemia. A peripheral blood smear, where a technician visually examines the blood cells, adds another layer of information that a standard automated blood count misses.
Benign Blood Disorders That Cloud the Picture
Some non-cancerous blood conditions generate lab results that sit uncomfortably close to leukemia. A leukemoid reaction, the body’s exaggerated immune response to a severe infection or inflammatory stress, can push the white blood cell count into a range that overlaps with early chronic myeloid leukemia. The two conditions can look similar even on a bone marrow biopsy. Research comparing them has found that while immunostaining patterns differ, the distinction requires specialized testing that not every lab performs as a first step.11PubMed. Immunophenotyping of early-phase chronic myeloid leukemia and leukemoid reaction
Immune thrombocytopenic purpura, a condition where the immune system destroys platelets, can also intersect with leukemia in confusing ways. A case report describes a 35-year-old woman diagnosed with ITP who developed acute myeloid leukemia ten months later.12PubMed Central. An Acute Leukaemia Masquerading as Immune Thrombocytopaenic Purpura (ITP)? A Case Report Whether the ITP was truly a separate condition or an early manifestation of the leukemia that eventually declared itself is exactly the kind of question that haunts retrospective reviews. Cancer cells in the marrow can suppress platelet production and trigger immune dysfunction that mimics autoimmune disorders, so the initial ITP diagnosis was not necessarily wrong at the time it was made. It just may have been incomplete.
The Blurry Line Between MDS and AML
Myelodysplastic syndrome and acute myeloid leukemia exist on a biological continuum, and the boundary between them has historically been a somewhat arbitrary line drawn at a specific blast percentage in the bone marrow. Patients with blast counts in the 20 to 29 percent range often look more like MDS patients in terms of age, genetics, and blood characteristics than like classic AML patients with very high blast counts.13PubMed Central. Interactions and relevance of blast percentage and treatment strategy among younger and older patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) This zone is genuinely contested in hematology, and a diagnosis can shift from MDS to AML (or back) depending on when the biopsy is taken and how the blasts are counted.14PubMed Central. Navigating the contested borders between myelodysplastic syndrome and acute myeloid leukemia For patients, this is not a mere academic distinction. MDS and AML often require different treatment approaches, and a patient who sits right at the threshold may receive conflicting opinions from different specialists.
A related problem arises with mixed phenotype acute leukemia, where the cancer cells express markers of more than one cell lineage. In a series of 218 consecutive acute leukemia cases evaluated by flow cytometry, about four percent were classified as MPAL. The finding that stands out is the authors’ note that MPAL can be missed entirely if the lab uses a limited panel of antibodies in its testing.15PubMed Central. Multiparametric Flow Cytometry in Mixed Phenotype Acute Leukemia Misclassifying MPAL as a straightforward ALL or AML can lead to treatment choices that are not well-matched to the biology of the disease.
When Leukemia Hides Behind a Normal Blood Count
One of the most counterintuitive presentations is aleukemic leukemia, where the cancer exists in the body without producing the elevated white cell count that doctors and patients both expect. A 72-year-old man presented with widespread lymph node enlargement but a completely normal blood count. Despite treatment for what appeared to be lymphoma, his lymph nodes continued to grow. It took 26 months before his white blood cell count finally spiked, at which point the diagnosis of T-cell prolymphocytic leukemia was confirmed.16PubMed. From the archives of MD Anderson Cancer Center: Aleukemic T-prolymphocytic leukemia, a rare presentation and review of the literature Cases like this challenge the assumption that leukemia will always announce itself through abnormal blood work.
Even when a bone marrow biopsy is performed, technical problems can interfere. A “dry tap,” where no liquid marrow can be aspirated through the needle, occurs in roughly four percent of procedures. In those cases, the overwhelming majority show significant marrow disease, often involving fibrosis or extreme cellularity. The conditions most frequently responsible included metastatic cancer, chronic myelogenous leukemia, and myelofibrosis.17PubMed. Dry tap bone marrow aspiration: clinical significance A dry tap is not a failure of the procedure so much as a diagnostic clue in itself, but it does mean the lab cannot perform the usual analysis on aspirated fluid, and follow-up biopsy or alternative techniques become necessary.
How Medications Can Mask the Diagnosis
Corticosteroids, commonly prescribed for inflammation, allergies, and autoimmune flares, have a particular ability to temporarily suppress leukemia cells and distort the bone marrow picture. A documented case of undiagnosed ALL involved a patient who received corticosteroids for unrelated symptoms before anyone suspected cancer. The steroids suppressed all blood cell lineages, effectively hiding the leukemic cells that would have otherwise been visible. Even a few doses were enough to alter the presentation significantly and delay diagnosis.18Medical Reports. A challenging case of acute lymphoblastic leukemia with bone marrow necrosis This is a particular concern in pediatric cases, where steroids might be prescribed for suspected asthma, allergic reactions, or the joint inflammation discussed earlier. The steroids can temporarily improve the child’s symptoms, which paradoxically reassures everyone that the initial benign diagnosis was correct.
Subtype Confusion Within Leukemia
Misdiagnosis does not only happen between leukemia and something else entirely. It also happens between different types of leukemia, and getting the subtype wrong can have serious treatment consequences. Acute promyelocytic leukemia, for instance, is treated with a highly specific regimen that differs substantially from standard AML therapy. Cases of AML with a particular genetic mutation (NPM1) have been documented presenting with abnormal clotting and low platelets in a pattern that closely resembles acute promyelocytic leukemia.19PubMed. Acute myeloid leukemia with mutated NPM1 mimics acute promyelocytic leukemia presentation Starting the wrong protocol based on a surface-level resemblance can mean a patient misses the treatment most likely to work for their actual disease while being exposed to unnecessary toxicity.
Modern diagnostics have gone well beyond looking at cells under a microscope. Accurate leukemia classification now integrates cell appearance, immunophenotyping (which identifies surface markers on cells), chromosome analysis, and molecular genetic testing. Next-generation sequencing has become increasingly central to AML diagnosis, allowing clinicians to identify specific mutations that determine prognosis and guide therapy.20PubMed Central. Advancing leukemia diagnostics: Role of Next Generation Sequencing (NGS) in acute myeloid leukemia But access to these tools is uneven. A community hospital may not have the same flow cytometry panel or molecular testing turnaround as a major academic center, and that gap creates real diagnostic risk.
Cognitive Bias and System-Level Failures
Not every misdiagnosis stems from tricky biology. A qualitative study examining how children with leukemia are diagnosed in primary care found that a wide range of non-disease factors contribute to delays, including tensions in the doctor-patient relationship and doctors’ cognitive biases.21BMJ Open. ‘Shouting from the roof tops’: a qualitative study of how children with leukaemia are diagnosed in primary care Anchoring bias, where a doctor fixates on an initial impression and filters subsequent information through it, is a well-known hazard in medicine. A child first seen for joint pain who gets labeled with arthritis may have that label reinforced at each follow-up visit, even as subtle signs of something more serious accumulate.
Resource-limited settings face compounding challenges. In many parts of Sub-Saharan Africa, healthcare workers may lack training to recognize leukemia’s signs, and the diagnostic tests needed to confirm it, such as bone marrow biopsies, flow cytometry, and genetic analysis, simply are not available in remote areas. The result is that leukemia often goes undetected until it has advanced to a stage where treatment options are limited and survival odds drop significantly.22PubMed Central. World Health Organization (WHO)’s vision for a leukemia-free Africa: opportunities and challenges- a narrative review Non-hematologic cancers that metastasize to the bone marrow can also enter the picture, producing drops in blood counts that mimic a primary blood cancer and further complicate diagnosis where sophisticated pathology is scarce.23Journal of Clinical and Translational Pathology. Bone Marrow Metastasis of Non-hematolymphoid Malignancies: A 10-Year Retrospective Experience from a Single Academic Institution
Does Diagnostic Delay Actually Affect Survival?
The relationship between diagnostic delay and outcomes in leukemia is less straightforward than you might expect. A meta-analysis and systematic review looking at time from diagnosis to treatment in AML found that several studies showed a link between longer delays and lower rates of achieving complete remission.24PubMed. Systematic review and meta-analysis: Prognostic impact of time from diagnosis to treatment in patients with acute myeloid leukemia An analysis of nearly 56,000 AML patients in the National Cancer Database found that in patients under 60, a five-day delay in starting chemotherapy was associated with slightly worse long-term survival, though the effect was small.25PubMed Central. Time from diagnosis to treatment is associated with survival in patients with acute myeloid leukaemia: An analysis of 55 985 patients from the National Cancer Database
Complicating this picture is what researchers call the waiting time paradox. Patients with the most aggressive disease tend to get diagnosed faster because their symptoms are impossible to ignore; they show up sicker and get worked up immediately. So the group with the shortest diagnostic intervals can paradoxically have the worst outcomes, not because speed failed them, but because their disease was inherently more lethal. A study from a middle-income country found that none of the measured interval delays were associated with early death, and intervals were actually longer in patients who did not die early.26PubMed Central. Are delays in diagnosis and treatment of acute leukemia in a middle-income country associated with poor outcomes? A retrospective cohort study This does not mean delay is harmless. It means the relationship between speed and survival is tangled up with disease biology in ways that make simple cause-and-effect claims unreliable.
When the Wrong Diagnosis Leads to the Wrong Treatment
The most dangerous misdiagnoses are not necessarily the longest delays. They are the ones that lead to active harm. A patient whose B12 deficiency gets mistaken for AML and who starts induction chemotherapy faces life-threatening toxicity from treatment they never needed. A child whose leukemia is treated as juvenile arthritis with anti-inflammatory drugs, including steroids, may have their cancer temporarily suppressed just enough to delay the real diagnosis while the disease progresses. A patient whose AML with a specific mutation gets treated as promyelocytic leukemia receives the wrong chemotherapy regimen entirely.
The recurring thread in these cases is not a single point of failure but a series of reasonable-seeming decisions that compound. A blood count that looks borderline. A rapid test that gives a misleading result. A bone marrow sample that is hard to interpret. A clinician who trusts a pattern they have seen a hundred times before. Each step makes sense in isolation. The problem is that leukemia, across its many subtypes, is genuinely protean in how it presents. Its symptoms overlap with infections, autoimmune conditions, nutritional deficiencies, and other cancers. Its lab findings can be subtle or misleading. And the diagnostic tools needed to pin it down with confidence require resources and expertise that are not universally available. For patients facing unexplained symptoms that are not resolving as expected, the practical takeaway is persistence: a diagnosis that does not explain a worsening clinical picture deserves to be questioned, regardless of how confident the initial assessment seemed.